JAK Inhibitors and biosimilars are among the rheumatoid arthritis warriors

mia.burns By Mia Burns The regulatory approval of baricitinib, a rheumatoid arthritis drug from Eli Lilly and Incyte, is predicted to prove paramount to the autoimmune community; however, ...

Facing A Tight Deadline, Long-Term Care Panel Holds First Meeting

barbara.lempert By Susan Jaffe KHN News Jun 28, 2013 The Commission on Long-Term Care held its first meeting Thursday on Capitol Hill with some members acknowledging that their ...

Officials Prepare For ‘Biggest Open-Enrollment Season We’ve Ever Seen’

barbara.lempert By Phil Galewitz and Jay Hancock KHN Staff Writers Jun 23, 2013 At the Silver State Health Insurance Exchange in Carson City, Nev., workers have been counting down ...

After 42 Years Email…Finally Clicks in the Pharmaceutical Industry

mia.burns Top 10 Ways to Secure a Competitive Edge with Compliant Email Communications By Paul Shawah Vice President, Commercial Strategy Veeva Systems Raymond Tomlinson, a software ...

Report: Low Interest Rates Impacting Retirement Funds

barbara.lempert New Research from EBRI: WASHINGTON—As many retirees and workers have discovered, today’s historically low interest rates are crimping their retirement savings. ...

Onyx shares skyrocket on report of Amgen buyout offer

John Carroll FierceBiotech News

State Says Hospital Improperly Claimed Reimbursement

barbara.lempert Missouri Improperly Claimed Federal Reimbursement for Most Reviewed Medicaid Inpatient Psychiatric Hospital Service and Disproportionate Share Hospital Payments to ...

Hospitals Honored for Improving Community Health

barbara.lempert Five Collaborative Programs Win AHA NOVA Award WASHINGTON (June 25, 2013) – The American Hospital Association (AHA) announced today that it will honor five programs ...

Pharma Companies Support Substantial Market Access Efforts from Phase 3a to Post-Launch

mia.burns Market access priorities shift from market research to health economics research during the launch process, finds Cutting Edge Information RESEARCH TRIANGLE PARK, N.C.–June ...

Study: Pharmas back market access efforts from Phase IIIa to post-launch

mia.burns By Mia Burns Pharmas tend to focus attention on market research in Phase IIIa to market approval and on health economics and outcomes research from launch to six months post-launch, ...

FDA approves Brisdelle, first nonhormonal treatment for hot flashes

Eric Palmer The FDA has approved the first nonhormonal treatment for hot flashes, which affect up to 75% of women and can drag on for 5 years or more. FiercePharma News

Soligenix Completes Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn’s Disease

barbara.lempert Princeton, NJ – June 28, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing ...
Page 2 of 6612345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS